About Vernalis
Vernalis is a company based in Wokingham (United Kingdom) founded in 1999 was acquired by HitGen in October 2020. It operates as a Professional Services. The company has 85 employees as of December 31, 2021. Vernalis has completed 4 acquisitions, including Cita NeuroPharmaceuticals, Ionix Pharmaceuticals and Pintex. Vernalis offers products and services including Fragment-Based Drug Discovery, DNA Encoded Library Technology, and Protein Science. Vernalis operates in a competitive market with competitors including Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Egalet, among others.
- Headquarter Wokingham, United Kingdom
- Employees 85 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vernalis (R&D) Limited
-
Annual Revenue
$12.23 K (USD)-39as on Dec 31, 2020
-
Net Profit
$-3.45 K (USD)58as on Dec 31, 2020
-
EBITDA
-
Latest Funding Round
$57.82 M (USD), Post-IPO
Apr 26, 2016
-
Investors
HitGen
& 5 more
-
Employee Count
85
as on Dec 31, 2021
-
Investments & Acquisitions
Cita NeuroPharmaceuticals
& 3 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vernalis
Vernalis offers a comprehensive portfolio of products and services, including Fragment-Based Drug Discovery, DNA Encoded Library Technology, and Protein Science. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Fragment-based methods are used for drug discovery programs.
DNA Encoded Library technology supports innovative drug discovery.
Protein expression and purification services are provided expertly.
Unlock access to complete
Funding Insights of Vernalis
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $57.8M
-
First Round
First Round
(18 Nov 2005)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2016 | Amount | Post-IPO - Vernalis | Valuation |
investors |
|
| Mar, 2016 | Amount | Grant - Vernalis | Valuation |
investors |
|
| Nov, 2005 | Amount | Post-IPO - Vernalis | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vernalis
Vernalis has secured backing from 6 investors, including institutional and angel investors. Prominent investors backing the company include HitGen, Ligand Pharmaceuticals and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment portfolios are managed for clients by the firm.
|
Founded Year | Domain | Location | |
|
Fund based investment management firm and fund of funds focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vernalis
Vernalis has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Cita NeuroPharmaceuticals, Ionix Pharmaceuticals and Pintex. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Analgesic medicines for acute and chronic pain are developed.
|
2001 | ||||
|
Small molecule neuropharmaceuticals are developed and commercialized for neurological disorders.
|
1997 | ||||
|
Small molecule therapeutics against cancer and infectious diseases
|
1997 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Vernalis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vernalis Comparisons
Competitors of Vernalis
Vernalis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Egalet, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| domain | founded_year | HQ Location |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| domain | founded_year | HQ Location |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for pain management are developed with abuse-deterrent designs.
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vernalis
Frequently Asked Questions about Vernalis
When was Vernalis founded?
Vernalis was founded in 1999 and raised its 1st funding round 6 years after it was founded.
Where is Vernalis located?
Vernalis is headquartered in Wokingham, United Kingdom. It is registered at Wokingham, Berkshire, United Kingdom.
How many employees does Vernalis have?
As of Dec 31, 2021, the latest employee count at Vernalis is 85.
What is the annual revenue of Vernalis?
Annual revenue of Vernalis is $12.23K as on Dec 31, 2020.
What does Vernalis do?
Vernalis is involved in enabling drug discovery programs through structure-based and fragment-based approaches. Expertise is applied in protein science, hit identification, and lead optimization across therapeutic areas like oncology and inflammatory diseases. Collaborations are established with various organizations to tackle challenging targets. Services are provided in-house at fully equipped laboratories in Cambridge, UK, covering biophysics, chemistry, and cell biology. Solutions are tailored for both short-term and long-term projects to deliver pre-clinical candidates.
Who are the top competitors of Vernalis?
Vernalis's top competitors include Flexion Therapeutics, Cara Therapeutics and Satsuma Pharmaceuticals.
What products or services does Vernalis offer?
Vernalis offers Fragment-Based Drug Discovery, DNA Encoded Library Technology, and Protein Science.
How many acquisitions has Vernalis made?
Vernalis has made 4 acquisitions, including Cita NeuroPharmaceuticals, Ionix Pharmaceuticals, and Pintex.
Who are Vernalis's investors?
Vernalis has 6 investors. Key investors include HitGen, Ligand Pharmaceuticals, European Union, Invesco Mutual Fund, and Woodford Investment Management.